Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says

(MedPage Today) -- The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by...